CathVision Secures CE Mark for ECGenius System, Expanding Cardiac Monitoring Capabilities in Europe

CathVision, a leading innovator in electrophysiology solutions, has announced CE Mark approval for its ECGenius System, a breakthrough technology designed to provide accurate real-time electrogram recording and AI-driven analytics. This certification allows CathVision to introduce its advanced cardiac monitoring technology to healthcare providers across the European Economic Area (EEA).

ECGenius System leverages cutting-edge signal processing and artificial intelligence to deliver precise insights for electrophysiologists, enhancing diagnostic accuracy and procedural efficiency. Already FDA 510(k) cleared in the U.S., the system is now set to expand its reach to European markets.

“We are thrilled to secure CE Mark approval for the ECGenius System, a milestone that reaffirms our commitment to delivering high-quality, innovative solutions in electrophysiology,” said Mads Matthiesen, CEO of CathVision. “This achievement validates the safety and efficacy of our technology and paves the way for broader global adoption.”

The CE Mark certification ensures that ECGenius System meets the stringent European Medical Device Regulation (MDR) requirements, complying with rigorous health, safety, and environmental protection standards. With this approval, CathVision is preparing for commercialization in Europe in the coming quarters while continuing to expand its customer base in the United States.